Evolut Low-Risk Trial 5-Year Result: We’re Halfway There

IF 21.7 1区医学 Q1 CARDIAC & CARDIOVASCULAR SYSTEMS

Journal of the American College of Cardiology Pub Date : 2025-03-30 DOI:10.1016/j.jacc.2025.03.428

Tsuyoshi Kaneko, Josep Rodés-Cabau, Alan Zajarias, Stephan Windecker

引用次数: 0

Abstract

Section snippets

Funding Support and Author Disclosures

Dr Kaneko has been a consultant for Medtronic, Edwards Lifesciences, Abbott Vascular, 4C Medical, Anteris, and Johnson & Johnson. Dr Rodés-Cabau has received institutional research grants and consultant/speaker fees from Edwards Lifesciences and Medtronic. Dr Zajarias has been a consultant for Edwards Lifesciences, Medtronic, and Anteris. Dr Windecker has received research, travel, and/or educational grants to the institution from Abbott, Abiomed, Alnylam, Amicus Therapeutics, Amgen,

查看原文本刊更多论文

求助全文

约1分钟内获得全文求助全文

来源期刊

Journal of the American College of Cardiology 医学-心血管系统

CiteScore

42.70

自引率

3.30%

发文量

5097

审稿时长

2-4 weeks

期刊介绍： The Journal of the American College of Cardiology (JACC) publishes peer-reviewed articles highlighting all aspects of cardiovascular disease, including original clinical studies, experimental investigations with clear clinical relevance, state-of-the-art papers and viewpoints. Content Profile: -Original Investigations -JACC State-of-the-Art Reviews -JACC Review Topics of the Week -Guidelines & Clinical Documents -JACC Guideline Comparisons -JACC Scientific Expert Panels -Cardiovascular Medicine & Society -Editorial Comments (accompanying every Original Investigation) -Research Letters -Fellows-in-Training/Early Career Professional Pages -Editor’s Pages from the Editor-in-Chief or other invited thought leaders